SCHEMBL5482327

SCHEMBL5482327

CN(Cc1ccc(Oc2ccc3c(c2)S(O)(O)NCN3CCF)cc1)S(C)(=O)=O

nearest known ligand 0.39

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
GRIA2 P42262 12/20 0.39
DRD2 P14416 1/20 0.33
DRD1 P21728 1/20 0.33
ACLY P53396 1/20 0.32
APLNR P35414 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5482325 0.90 GRIA2 (0.51) GRIA2DRD2DRD1
SCHEMBL5485316 0.89 GRIA2 (0.37) GRIA2APLNR
SCHEMBL5479955 0.84 GRIA2 (0.39) GRIA2
SCHEMBL5482709 0.82 LTA4H (0.41) GRIA2
SCHEMBL5481775 0.79 GRIA2 (0.49) GRIA2APLNR
SCHEMBL5477040 0.78 GRIA2 (0.39) GRIA2
SCHEMBL5484644 0.78 GRIA2 (0.40) GRIA2DRD2
SCHEMBL5479901 0.75 GRIA2 (0.39) GRIA2
SCHEMBL5481528 0.75 GRIA2 (0.39) GRIA2
SCHEMBL5479962 0.74 GRIA2 (0.52) GRIA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1655030-B1 Benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same SERVIER LAB (FR) 2007-12-19 EP disclosed
US-7268130-B2 Benzothiadiazine compounds LES LABORATOIRES SERVIER (FR) 2007-09-11 US disclosed
EP-1655030-A1 Benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same Les Laboratoires Servier (FR) 2006-05-10 EP disclosed
US-20060094712-A1 New benzothiadiazine compounds LES LABORATOIRES SERVIER (FR) 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094712-A1 New benzothiadiazine compounds SLC1A1, SLC1A2, GABRA5 GRIA2 36/4885DRD2 341/4885DRD1 353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.